Ep. 309 - 3Q Markets Preview; Quantum Computing; Makary’s First 100 Days

Chinese biotech is the lone bright spot for the biopharma financial markets in 1H25, as macro concerns about the most favored nation (MFN) pricing policy and FDA weigh on the prospects for biotech elsewhere. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the positives — and negatives — impacting investor sentiment headed into the second half of the year. The team also discuss where the quantum computing revolution could have its biggest impact on drug development, and review the proposals and accomplishments of FDA Commissioner Marty Makary over his first 100 days in office. This episode of BioCentury This Week was sponsored by IQVIA Biotech. View full story: https://www.biocentury.com/article/656482 #biotech #biopharma #pharma #lifescience #financialmarkets #FDA #quantumcomputing 00:01 - Sponsor Message: IQVIA Biotech 04:43 - Q25 Financial Markets Preview 22:20 - Quantum Computing Impact on Biopharma 30:07 - Makary"s First 100 Days To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text